PACTT is proud to announce that Sulfiscon SA, a CHUV’s spin-off, led by the Dr. Alexander So, has received an Innosuisse financing to further the development of its innovative technology for the treatment of osteoarthritis, the most common degenerative disorder of the joints that affects more than half the elderly population worldwide. The project will be conducted in conjunction with Dr. Rainer Riedl from the Zurich University of Applied Sciences (ZHAW) and Dr. Sonia Nasi from the CHUV.
Dr. So and its Sulfiscon’s team were previously awarded in fall 2014 a FIT InnoTREK PACTT grant so as to complete an initial development phase of their technology tackling the root cause of osteoarthritis, a revolutionary approach to treat rather than only alleviate the pain as it is the case still today.